Recently, a placebo controlled clinical study evaluated the effect of rFeIFN-omega treatment in cats. A single subcutaneous dose of rFeIFN-omega followed by topical treatment for 21 days did not improve the outcome, compared to placebo, in acute upper respiratory viral disease caused by FHV-1.